Rheos Medicines appoints Roche Senior Vice President and R&D head as new CEO

pharmafile | September 6, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, CEO, Roche, cembridge, massachussets, rheos, sanjay keswani 

The Cambridge Massachusetts-based biopharmaceutical company Rheos Medicines has appointed former Roche Senior Vice President and Global R&D Head, Dr Sanjay Keswani as their new Chief Executive Officer (CEO).

“Sanjay’s broad drug development experience across multiple therapeutic areas and strong track record for building high performing teams is an ideal fit for Rheos at this time when the productivity of the company’s product engine ramps up to generate initial drug programs as well as a range of therapeutic opportunities to address many immune-mediated diseases through novel targets and concurrent biomarker approach,” said interim CEO Dr Abbie Celniker, who will remain on Rheos Medicine’s board of directors as Chairwoman.

Having graduated with a first class degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology), Dr Keswani went on to complete his medical residency in Neurology and Neuroscience at The Johns Hopkins University School of Medicine where he later took on the role of assistant professor.

The experienced doctor made his transition into the pharmaceutical industry taking on R&D leadership roles first at Amgen and Eli Lilly and then later taking on positions at Roche where he served as Senior Vice President and Global Head of Neuroscience and Bristol-Myers Squibb where he took on the role of Vice President, Exploratory and Clinical Translational Research.  

“I am excited to join the world-class team at Rheos Medicines and be a part of the pioneering effort to translate the company’s leading-edge insights and product engine in immunometabolism into novel treatments for a broad range of patients with immune-mediated diseases and cancer,” said Sanjay Keswani. “There is an immense opportunity to change the therapeutic paradigm for treating diseases that involve the immune system, and Rheos is ideally positioned to set a new standard by targeting the underlying cellular metabolism of immune cells to treat a wide range of diseases.”

Related Content

Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …

Roche announces acquisition of Telavant

Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, …

EC approves Roche’s Evrysdi for babies under two months with SMA

Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing …

Latest content